Insights into Rat Model Market: Size, Share, and Trends 2024-2033

The Rat Model Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Rat Model Market:

https://www.thebusinessresearchcompany.com/report/rat-model-global-market-report

According to The Business Research Company’s Rat Model Global Market Report 2024, The rat model market size has grown strongly in recent years. It will grow from $1.56 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising demand for preclinical research, increasing government funding, research demand, drug development initiatives, rising chronic disease.

The rat model market size is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to expanding applications in personalized medicine, growing demand for animal models in drug discovery, increasing focus on disease prevention, expansion of biopharmaceutical industry, innovation in imaging techniques, government and private funding. Major trends in the forecast period include global collaborations in research, technological advancements in imaging, integration of omics technologies, advancements in genome editing techniques, growing importance of rat models in disease research, rise of personalized medicine and customized rat models.

The rising incidence of chronic diseases is expected to boost the growth of the rat model market going forward. Chronic diseases refer to conditions that last for a year or longer, hinder everyday activities, demand continuous medical care, or both. Rat models have been instrumental in studying the pathogenesis, immune responses, and treatment of chronic infections, providing valuable insights that can inform the development of new therapies and interventions. For instance, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, in 2023, in the United States, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity would rise by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. Therefore, the rising incidence of chronic diseases is driving the growth of the rat model market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10100&type=smp

The rat model market covered in this report is segmented –

1) By Type: Knockout, Outbred, Inbred, Hybrid, Immunodeficient, Conditioned

2) By Service: Cryopreservation, Breeding, Re-derivation, Genetic Testing, Quarantine Depending, Other Services

3) By Technology: Nuclear Transferase, Microinjection, Embryonic Stem Cell, Other Technologies

4) By Application: Oncology, Neurology, Immunology, Toxicology, Other Applications

Major companies operating in the rat model market are developing strategic partnerships for preclinical research in oncology and other therapeutic areas. Collaborating with the companies operating in the rat model enables them to focus on their core business while leveraging the efficiency and cost-effectiveness of these specialized providers, which have established infrastructure and resources for generating rat models. For instance, in March 2022, Hera BioLabs, a US-based biotechnology company partnered with Charles River Laboratories, International Inc., a US-based pharmaceutical company for the commercialization of Hera’s SRG rat, also known as OncoRat. Under this collaboration, Charles River will breed, distribute, sell, and market the SRG rat directly to the preclinical research community. The SRG rat is a highly immunodeficient rat that is ideal for xenograft or PDX studies, providing unique advantages over mouse models for conducting in vivo efficacy evaluation of potential cancer therapies. The model overcomes the limitations of smaller mouse models, enabling larger tumor growth, easier surgeries, and more tissues and serum for analyses, including repeat sampling.

The rat model market report table of contents includes: